These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 33512442)

  • 1. A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis.
    Kennedy GA; Tey SK; Buizen L; Varelias A; Gartlan KH; Curley C; Olver SD; Chang K; Butler JP; Misra A; Subramoniapillai E; Morton AJ; Durrant S; Henden AS; Moore J; Ritchie D; Gottlieb D; Cooney J; Paul SK; Hill GR
    Blood; 2021 Apr; 137(14):1970-1979. PubMed ID: 33512442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
    Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
    Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.
    Soiffer RJ; Kim HT; McGuirk J; Horwitz ME; Johnston L; Patnaik MM; Rybka W; Artz A; Porter DL; Shea TC; Boyer MW; Maziarz RT; Shaughnessy PJ; Gergis U; Safah H; Reshef R; DiPersio JF; Stiff PJ; Vusirikala M; Szer J; Holter J; Levine JD; Martin PJ; Pidala JA; Lewis ID; Ho VT; Alyea EP; Ritz J; Glavin F; Westervelt P; Jagasia MH; Chen YB
    J Clin Oncol; 2017 Dec; 35(36):4003-4011. PubMed ID: 29040031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
    Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
    Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.
    Kennedy GA; Varelias A; Vuckovic S; Le Texier L; Gartlan KH; Zhang P; Thomas G; Anderson L; Boyle G; Cloonan N; Leach J; Sturgeon E; Avery J; Olver SD; Lor M; Misra AK; Hutchins C; Morton AJ; Durrant ST; Subramoniapillai E; Butler JP; Curley CI; MacDonald KPA; Tey SK; Hill GR
    Lancet Oncol; 2014 Dec; 15(13):1451-1459. PubMed ID: 25456364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study.
    Yeshurun M; Shpilberg O; Herscovici C; Shargian L; Dreyer J; Peck A; Israeli M; Levy-Assaraf M; Gruenewald T; Mechoulam R; Raanani P; Ram R
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1770-5. PubMed ID: 26033282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD.
    Watkins B; Qayed M; McCracken C; Bratrude B; Betz K; Suessmuth Y; Yu A; Sinclair S; Furlan S; Bosinger S; Tkachev V; Rhodes J; Tumlin AG; Narayan A; Cribbin K; Gillespie S; Gooley TA; Pasquini MC; Hebert K; Kapoor U; Rogatko A; Tighiouart M; Kim S; Bresee C; Choi SW; Davis J; Duncan C; Giller R; Grimley M; Harris AC; Jacobsohn D; Lalefar N; Norkin M; Farhadfar N; Pulsipher MA; Shenoy S; Petrovic A; Schultz KR; Yanik GA; Waller EK; Levine JE; Ferrara JL; Blazar BR; Langston A; Horan JT; Kean LS
    J Clin Oncol; 2021 Jun; 39(17):1865-1877. PubMed ID: 33449816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
    Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
    Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
    J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
    Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.
    Pérez-Simón JA; Díez-Campelo M; Martino R; Brunet S; Urbano A; Caballero MD; de León A; Valcárcel D; Carreras E; del Cañizo MC; López-Fidalgo J; Sierra J; San Miguel JF
    Br J Haematol; 2005 Aug; 130(3):394-403. PubMed ID: 16042689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Tacrolimus and Cyclosporine Combined With Methotrexate for Graft Versus Host Disease Prophylaxis After Allogeneic Hematopoietic Cell Transplantation.
    Huang B; Lin X; Zhang Z; Zhang Y; Zheng Z; Zhong C; He X; Chen M
    Transplantation; 2020 Feb; 104(2):428-436. PubMed ID: 31283681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of a low fixed number of CD3+ cells to CD34-enriched allografts: effects on engraftment, graft-versus-host disease, and survival after related and unrelated peripheral stem cell transplantation.
    Goerner M; Weber-Nordt R; Hoepfner S; Benner A; Luft T; Ho AD
    J Hematother Stem Cell Res; 2003 Jun; 12(3):309-20. PubMed ID: 12857372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial.
    Finke J; Schmoor C; Bethge WA; Ottinger H; Stelljes M; Volin L; Heim D; Bertz H; Grishina O; Socie G
    Lancet Haematol; 2017 Jun; 4(6):e293-e301. PubMed ID: 28583289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical study on haploid HLA-matched hematopoietic stem cell transplantation for treatment of malignant hematological disease].
    Sun AN; Wu DP; Wang Y; Qiu HY; Jin ZM; Miao M; Tang XW; Fu ZZ; Ma X; Han Y; He GS; Chen SN; Xue SL; Zhao Y
    Ai Zheng; 2006 Aug; 25(8):1019-22. PubMed ID: 16965686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity.
    Bertz H; Potthoff K; Mertelsmann R; Finke J
    Bone Marrow Transplant; 1997 Jun; 19(12):1169-73. PubMed ID: 9208109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study on graft-versus-host disease in the allogeneic peripheral blood stem cell transplantation for the treatment of leukemia].
    Zhang WP; Wang JM; Ju XP; Song XM; Tong SP; Li HM
    Zhonghua Xue Ye Xue Za Zhi; 2003 Mar; 24(3):129-33. PubMed ID: 12697123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-
    Drobyski WR; Szabo A; Zhu F; Keever-Taylor C; Hebert KM; Dunn R; Yim S; Johnson B; D'Souza A; Eapen M; Fenske TS; Hari P; Hamadani M; Horowitz MM; Rizzo JD; Saber W; Shah N; Shaw B; Pasquini M
    Haematologica; 2018 Apr; 103(4):717-727. PubMed ID: 29351985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.